Briquilimab for Hives
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial evaluates the safety and effectiveness of briquilimab (also known as JSP191 or AMG-191) for individuals with persistent hives. It specifically targets those who previously tried briquilimab in a study without severe allergic reactions. The trial seeks participants who recently completed a Jasper-sponsored study on hives and continue to experience significant symptoms, such as frequent hives or skin reactions to cold. Participants must agree to refrain from donating blood during the trial. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important findings.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that briquilimab is likely to be safe for humans?
Previous studies have shown that briquilimab is well tolerated. Researchers reported no serious side effects, and even minor side effects were rare. Research indicates that patients experienced either no side effects or only mild ones. This suggests briquilimab could be a safe option for treating hives. Ongoing studies will continue to assess its long-term safety.12345
Why do researchers think this study treatment might be promising?
Unlike the standard care for hives, which often includes antihistamines and corticosteroids to manage symptoms, Briquilimab offers a fresh approach by using a new mechanism of action. Briquilimab is administered via a subcutaneous injection and works by targeting specific pathways involved in the allergic response, potentially providing more direct and effective control of hives. Researchers are excited about Briquilimab because it might offer a faster and more sustained relief compared to traditional treatments, improving the quality of life for patients with chronic hives.
What evidence suggests that briquilimab might be an effective treatment for hives?
Research has shown that briquilimab, which participants in this trial will receive, may effectively treat hives. In one study, 14 out of 15 people saw improvement, and in a group taking a 120mg dose, 10 out of 12 experienced complete relief. Another study found that with a 180mg dose, all 12 participants achieved strong symptom control. Additionally, single doses of 240mg and 360mg resulted in 89% of participants experiencing complete relief. These findings suggest briquilimab could help manage hives.23467
Who Is on the Research Team?
Medical Director
Principal Investigator
Jasper Therapeutics
Are You a Good Fit for This Trial?
This trial is for individuals who have previously participated in Jasper-sponsored Chronic Urticaria (CU) trials. It's designed to assess the long-term safety and effectiveness of a medication called Briquilimab for those with chronic hives or urticaria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Open-label Extension
Participants receive briquilimab via SQ injection to evaluate long-term safety and clinical activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Briquilimab
Briquilimab is already approved in European Union for the following indications:
- Orphan designation for conditioning treatment prior to hematopoietic stem cell transplant in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), Fanconi anemia (FA), and sickle cell disease (SCD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jasper Therapeutics, Inc.
Lead Sponsor